WuXi Biologics (Cayman) (HKG:2269) recorded a 1.3% decline in attributable profit for the year 2024 to 3.36 billion yuan from 3.4 billion yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse said.
Earnings per share were 0.78 yuan in the year, up from 0.77 yuan in the previous corresponding year.
The vaccine maker's revenue rose by 9.6% to 18.7 billion yuan in the year from 17 billion yuan a year prior.
The higher revenue was mainly due to the successful execution of the company's "Follow and Win the Molecule" strategies, an enlarged spectrum of services offered to the biologics industry, growth of research services revenue, and the utilization of existing and newly expanded capacities.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。